Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in...

Area of Science:

• Neuroscience
• Neurology
• Genetics

Background:

• Central nervous system (CNS) involvement in myotonic dystrophy type 1 (DM1) significantly impacts quality of life through cognitive deficits, social impairment, and somnolence.
• Valid and feasible outcome measures are crucial for DM1 clinical trials to quantify CNS symptoms.

Purpose of the Study:

• To evaluate the validity and specificity of recommended neuropsychological and self-reported measures for CNS involvement in DM1.
• To assess the relationship between cognitive function, mood, and brain imaging findings in DM1.

Main Methods:

• Forty-five DM1 patients and 20 controls underwent neuropsychological testing and symptom questionnaires.
• Brain MRI was used to quantify gray matter volume and white matter lesions.
• CTG repeat length and variant repeat sequences were analyzed.

Main Results:

• Neuropsychological tests revealed impairments in DM1 patients, but large effect sizes were reduced by motor speed corrections.
• Low mood strongly correlated with self-reported cognitive issues.
• Self-reported cognitive problems did not consistently predict objective test performance; mood and white matter changes showed a trend.

Conclusions:

• Developing specific outcome measures for DM1 CNS involvement is difficult due to confounding factors like peripheral weakness and mood.
• Further large, longitudinal studies are needed to identify and validate objective measures, potentially including neuroimaging biomarkers and motor-speed-independent cognitive tests.